<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000752'>Hyperactivity</z:hpo> of coagulation factor VIII (fVIII) marks hypercoagulation </plain></SENT>
<SENT sid="1" pm="."><plain>FVIII enhances activity of factor IX and their combination activates factor X, which is of primary importance in prothrombin transformation into thrombin, on the <z:chebi fb="0" ids="16247">phospholipid</z:chebi> membrane </plain></SENT>
<SENT sid="2" pm="."><plain>The activity of fVIII was studied in 28 patients (26 women, 2 men, mean age 49.6 +/- 7.8 years) with <z:e sem="disease" ids="C0282492" disease_type="Disease or Syndrome" abbrv="">Sneddon's syndrome</z:e> (SS) </plain></SENT>
<SENT sid="3" pm="."><plain>SS manifests clinically similarly to <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (<z:chebi fb="61" ids="27565">PAS</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>The leading of them are ischemic disorders of cerebral circulation (IDCC) and advanced livedo present in <z:hpo ids='HP_0000001'>all</z:hpo> the examinees </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000752'>Hyperactivity</z:hpo> of fVIII was registered in 21 (75%) of 28 patients </plain></SENT>
<SENT sid="6" pm="."><plain>Most of <z:mp ids='MP_0005048'>thrombosis</z:mp>-related symptoms occurred more frequently in patients with high than <z:mpath ids='MPATH_458'>normal</z:mpath> activity of fVIII: <z:hpo ids='HP_0002140'>ischemic strokes</z:hpo> (91% vs 57%, p &gt; 0.05), repeated <z:hpo ids='HP_0001297'>strokes</z:hpo> (71% vs 0%, p = 0.0014), transient IDCC (76% vs 57%, p &gt; 0.05), vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (43% vs 0%, p &gt; 0.05), <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> (43% vs 0%, p &gt; 0.05), thickening of heart valves according to echocardiography (91% vs 57%, p &gt; 0.05), peripheral venous thromboses (24% vs 0%, p &gt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>In high fVIII activity <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies occurred more rarely (24% vs 43%, p &gt; 0.05) but <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was seen more often (47% vs 14%, p &gt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>High fVIII activity was in 8 of 12 aPL-negative patients </plain></SENT>
<SENT sid="9" pm="."><plain>It is demonstrated that elevated fVIII activity is an essential mechanism of <z:mp ids='MP_0005048'>thrombosis</z:mp> development in SS </plain></SENT>
<SENT sid="10" pm="."><plain>The cause of this enhanced activity is suggested to be special aPL in interaction with which fVIII becomes insensitive to inactivation with protein C </plain></SENT>
<SENT sid="11" pm="."><plain>The activity of protein C was <z:mpath ids='MPATH_458'>normal</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> the cases </plain></SENT>
</text></document>